Apimeds Pharmaceuticals US (APUS) Common Equity (2023 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Common Equity came in at $153.3 million in Q4 2025, up 11391.18% YoY from N/an in Q4 2024, and up 1779.11% on a QoQ basis from $8.2 million in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Common Equity (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 3 years of Common Equity data on file, last reported at $153.3 million in Q4 2025.
- Quarterly Common Equity rose 11391.18% year-over-year to $153.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $153.3 million (up 11391.18% YoY) and the FY2025 annual result came in at $153.3 million, up 11391.18% from the prior year.
- Common Equity rose to $153.3 million in Q4 2025, from $8.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $153.3 million in Q4 2025 to a low of -$1.8 million in Q1 2025.
- A 3-year average of $18.5 million and a median of -$264604.0 in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity plunged 4361.57% — and 2025, when it jumped 11391.18%.
- Tracing APUS's Common Equity over 3 years: stood at $31869.0 in 2023, then sank by 4361.57% to -$1.4 million in 2024, then jumped by 11391.18% to $153.3 million in 2025.
- The last three Common Equity figures came in at $153.3 million (Q4 2025), $8.2 million (Q3 2025), and $9.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Apimeds Pharmaceuticals US | 7.20 Mn | 7.20 Mn | - | 106.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 153.35 Mn |
| Sep 30, 2025 | 8.16 Mn |
| Jun 30, 2025 | 9.74 Mn |
| Mar 31, 2025 | -1.76 Mn |
| Dec 31, 2024 | -1.36 Mn |
| Sep 30, 2024 | -1.05 Mn |
| Jun 30, 2024 | -713,967.00 |
| Mar 31, 2024 | -264,604.00 |
| Dec 31, 2023 | 31,869.00 |